NEW YORK, June 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Medical Action Industries Inc. (NASDAQ: MDCI), INSYS Therapeutics, Inc. (NASDAQ: INSY), Novadaq Technologies Inc. (NASDAQ: NVDQ) and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4239-100free.
--
Aerie Pharmaceuticals, Inc. Analyst Notes
On June 16, 2014, Aerie Pharmaceuticals, Inc. (Aerie) announced the appointment of Craig R. Skenes as the Company's Vice President, Business Development. "Craig's extensive business development expertise, particularly in ophthalmology, will be a great asset for us as we chart the next stage in Aerie's growth and our strategic partnering options," said Vicente Anido, Jr., Ph.D., Chairman and CEO of Aerie. "Our lead product candidates, Rhopressa™, entering Phase 3 testing, and Roclatan™, completing Phase 2b, are highly differentiated therapies, and we believe we have the opportunity to generate substantial interest for these products among potential collaborators. This is an opportune time to join Aerie in a business development role. I believe Aerie has a highly accomplished and dynamic leadership team and promising product candidates addressing clear and substantial market needs." The full analyst notes on Aerie are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/AERI/report.pdf
--
Medical Action Industries Inc. Analyst Notes
On June 25, 2014, Medical Action Industries Inc. (Medical Action) announced that it has signed a definitive agreement with Owens & Minor, Inc., (Owens & Minor) under which the latter will acquire all outstanding shares of Medical Action for $13.80 per share in cash, representing a total transaction value of c.$208 million, including assumed debt, net of cash. "Owens & Minor's position as a leading healthcare logistics company will be complemented by the talented Medical Action employees who provide quality products and solutions that improve patient outcomes," said Paul D. Meringolo, CEO of Medical Action. "Our companies have enjoyed a highly collaborative relationship for over thirty-five years, are built around similar cultures and values and are respected throughout the healthcare community. This transaction represents an excellent outcome for stockholders, employees and customers, who will benefit from the reputation, expertise and knowledge provided by the combined companies." The transaction is expected to be accretive to Owens & Minor's non-GAAP net income in 2015. The full analyst notes on Medical Action are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/MDCI/report.pdf
--
INSYS Therapeutics, Inc. Analyst Notes
On June 25, 2014, Insys Therapeutics, Inc. (Insys) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. "With no cure and persistence of seizures with current antiepileptic medications, the orphan drug designation recognizes the significant, unmet need that exists among children with this severe form of epilepsy and the teams who provide their care," said Michael L. Babich, President and CEO of Insys. "We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application (IND) for CBD in the second half of 2014." The full analyst notes on INSYS are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/INSY/report.pdf
--
Novadaq Technologies Inc. Analyst Notes
On June 25, 2014, Novadaq Technologies Inc.'s stock increased 5.33% to end the day at $16.01 compared to the previous day's closing price of $15.20. The Company's stock increased 6.87% over the past one trading month compared to the Nasdaq Composite which rose 4.62% during the same trading period. The full analyst notes on Novadaq are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/NVDQ/report.pdf
--
Foundation Medicine, Inc. Analyst Notes
On June 16, 2014, Foundation Medicine Inc. (Foundation Medicine) reported that it has joined a unique public-private collaboration with the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies -Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune, for the Lung Cancer Master Protocol (Lung-MAP) trial. According to the Company, the Lung-MAP is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer. Foundation Medicine stated that the trial will initially test five experimental drugs-four targeted therapies and an anti-PD-L1 immunotherapy, and it is anticipated that between 500 and 1000 patients will be screened per year for over 200 cancer-related genes for genomic alterations. The results of this test will be used to assign each patient to the trial arm that is best matched to their tumor's genomic profile. "This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial," said Dr. Ellen Sigal, Chair & Founder of Friends of Cancer Research. The full analyst notes on Foundation Medicine are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/FMI/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
